TY - JOUR
T1 - Neuroprotective effect of CuATSM in mice stroke model by ameliorating oxidative stress
AU - Shi, Xiaowen
AU - Ohta, Yasuyuki
AU - Nakano, Yumiko
AU - Liu, Xia
AU - Tadokoro, Koh
AU - Feng, Tian
AU - Nomura, Emi
AU - Tsunoda, Keiichiro
AU - Sasaki, Ryo
AU - Matsumoto, Namiko
AU - Osakada, Yosuke
AU - Bian, Yuting
AU - Bian, Zhihong
AU - Omote, Yoshio
AU - Takemoto, Mami
AU - Hishikawa, Nozomi
AU - Yamashita, Toru
AU - Abe, Koji
PY - 2020
Y1 - 2020
N2 - Cu-diacetyl-bis (N4-methylthiosemicarbazone) (CuATSM) has both anti-oxidative and anti-inflammatory activities, but its therapeutic efficacy for oxidative stress has not been thoroughly investigated in acute ischemic stroke. Here, the present study was designed to assess the efficacies of CuATSM in acute ischemic stroke by comparing with the standard neuroprotective reagent edaravone. Mice were subjected to transient middle cerebral occlusion (tMCAO) for 60 min, and then intravenously administrated with CuATSM (1.5 mg/kg) or edaravone (3 mg/kg) just after the reperfusion, and examined at 1 and 3 d. Compared with the vehicle group, CuATSM treatment decreased infarct volumes and oxidative stress at 3d after tMCAO, which was further enhanced by combined CuATSM + edaravone treatment as compared with single CuATSM group, but not improve neurobehaviors. The present study demonstrated that CuATSM showed strong antioxidative and neuroprotective effects in acute ischemic stroke, which was enhanced by the combination with edaravone.
AB - Cu-diacetyl-bis (N4-methylthiosemicarbazone) (CuATSM) has both anti-oxidative and anti-inflammatory activities, but its therapeutic efficacy for oxidative stress has not been thoroughly investigated in acute ischemic stroke. Here, the present study was designed to assess the efficacies of CuATSM in acute ischemic stroke by comparing with the standard neuroprotective reagent edaravone. Mice were subjected to transient middle cerebral occlusion (tMCAO) for 60 min, and then intravenously administrated with CuATSM (1.5 mg/kg) or edaravone (3 mg/kg) just after the reperfusion, and examined at 1 and 3 d. Compared with the vehicle group, CuATSM treatment decreased infarct volumes and oxidative stress at 3d after tMCAO, which was further enhanced by combined CuATSM + edaravone treatment as compared with single CuATSM group, but not improve neurobehaviors. The present study demonstrated that CuATSM showed strong antioxidative and neuroprotective effects in acute ischemic stroke, which was enhanced by the combination with edaravone.
KW - CuATSM
KW - Edaravone
KW - Oxidative stress
KW - Stroke
KW - Transient middle cerebral artery occlusion
UR - http://www.scopus.com/inward/record.url?scp=85085922054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085922054&partnerID=8YFLogxK
U2 - 10.1016/j.neures.2020.05.009
DO - 10.1016/j.neures.2020.05.009
M3 - Article
C2 - 32461139
AN - SCOPUS:85085922054
JO - Neuroscience Research
JF - Neuroscience Research
SN - 0168-0102
ER -